Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers
- 15 May 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (10), 2732-2746
- https://doi.org/10.1158/0008-5472.CAN-17-1990
Abstract
Activation of PI3K signaling is frequently observed in triple-negative breast cancer (INBC), yet PI3K inhibitors have shown limited clinical activity. To investigate intrinsic and adaptive mechanisms of resistance, we analyzed a panel of patient-derived xenograft models of 'NBC with varying responsiveness to sib, a pan-PI3K inhibitor. In a subset of patient-derived xenografis, resistance was associated with incomplete inhibition of PI3K signaling and upregulated MAPK/MEK signaling in response to buparhsib. Outlier phosphoproteome and kinome analyses identified novel candidates functionally important to buparlisib resistance, including NEK9 and MAP2K4. Knockdown of NEK9 or MAP2K4 reduced both baseline and feedback MAPK/MEK signaling and showed synthetic lethality with buparlisib in Wm. A complex in/del frantesliift in PIK3CA decreased sensitivity to buparlisib via NEK9/MAP2K4 -dependent mechanisms. In summary, our study supports a role for NEK9 and MAP2K4 in mediating bupadisib resistance and demonstrates the value of unbiased omic analyses in uncovering resistance mechanisms to targeted therapy. Significance: Integrative phosphoproteogenomic analysis is used to determine intrinsic resistance mechanisms of triple-negative breast tumors to PI3K inhibition. (C) 2018 AACR.Other Versions
Funding Information
- HHS | National Institutes of Health (NIH) (U24CA160034)
- HHS | NIH | National Cancer Institute (NCI) (U24CA210972)
- Leidos (13XS068)
- HHS | NIH | National Cancer Institute (NCI) (CA058223)
- HHS | NIH | National Cancer Institute (NCI) (U24CA210986)
- HHS | NIH | National Cancer Institute (NCI) (U24CA160035)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP170005)
- HHS | NIH | National Cancer Institute (NCI) (P30CA125123)
- The Proteomics Shared Resources at Washington University and the Siteman Cancer Center (NCI P30 CA091842)
- Susan G. Komen for the Cure (Susan G. Komen) (IIR13263475)
- Vetenskapsrådet (VR) (Dnr 2014-323)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RR140033)
This publication has 49 references indexed in Scilit:
- Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor modelsJCI Insight, 2012
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- RAS Interaction with PI3K: More Than Just Another Effector PathwayGenes & Cancer, 2011
- Genome remodelling in a basal-like breast cancer metastasis and xenograftNature, 2010
- Epidermal Growth Factor Receptor Phosphorylation Sites Ser991 and Tyr998 Are Implicated in the Regulation of Receptor Endocytosis and Phosphorylations at Ser1039 and Thr1041Molecular & Cellular Proteomics, 2009
- Site-Specific mTOR Phosphorylation Promotes mTORC1-Mediated Signaling and Cell GrowthMolecular and Cellular Biology, 2009
- Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cellsBreast Cancer Research, 2008
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Glycogen Synthase Kinase-3 Inhibition Induces Glioma Cell Death through c-MYC, Nuclear Factor-κB, and Glucose RegulationCancer Research, 2008
- Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylationThe EMBO Journal, 2007